Safety Study of Lifitegrast to Treat Dry Eye

Phase 3

Completed

• Conditions: Dry Eye Disease
• Interventions: Drug: Placebo; Drug: Lifitegrast

• Registration Number: NCT01636206
• Lead Sponsor: Shire

Brief Summary

The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-07-05
• Study First Submitted QC: 2012-07-05
• Study First Posted: 2012-07-10
• Study Start: 2012-10-16
• Primary Completion: 2014-03-03
• Study Completion: 2014-03-03
• Disposition First Submitted: 2014-04-07
• Disposition First Submitted QC: 2014-04-07
• Disposition First Posted: 2014-05-01
• Results First Submitted: 2016-08-09
• Results First Submitted QC: 2016-08-09
• Results First Posted: 2016-10-03
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-02
• Last Update Posted: 2021-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 332

Inclusion Criteria

• Willing and able to read, sign and date the informed consent and HIPAA documents
• Willing and able to comply with all study procedures
• Be at least 18 years of age
• Patient-reported history of dry eye in both eyes
• A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

Exclusion Criteria

• Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
• Unwilling to avoid wearing contact lenses for 24h prior to Visit 1 and for some duration during the study
• Any blood donation or significant loss of blood within 56 days of Visit 1
• Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
• Use of any prohibited medications during the appropriate pre-study washout period and at any time during the study unless otherwise specified
• Any significant illness that could interfere with study parameters
• History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
• Known history of alcohol and/or drug abuse
• Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo
Lifitegrast	Lifitegrast	Active

Primary Outcome Measures

Name	Time	Method
Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year	Day 0 to Day 360

Trial Locations

Locations (1)

SONATA Investigational Site; 🇺🇸 Houston, Texas, United States